The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up

Jung, Minkyu; Shin, Hyun Joon; Rha, Sun Young; Jeung, Hei Cheul; Hong, Soojung; Moon, Yong Wha; Kim, Hyo Song; Oh, Kyung Jin; Yang, Woo Ick; Roh, Jae Kyung; Chung, Hyun Cheol

doi:10.1245/s10434-010-1172-3

Cited by 42 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, amenorrhea rates become pronounced in patients' C40 years of age [34] but many studies do not stratify by age. In addition, the very limited data on women under 35 show extremely low rates of CIA (0-10% in most studies) [35]. Although the diagnosis of breast cancer is rare in this age group, definitive data would be extremely useful as these women are most likely to have not completed child-bearing.…”

Section: Methodsmentioning

confidence: 99%

Pregnancy after breast cancer: if you wish, ma’am

Pagani

Partridge

Korde

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

A growing number of young breast cancer survivors consider reproductive health issues, including subsequent fertility and pregnancy, of great importance, but many questions regarding safety remain unanswered. We conducted a comprehensive literature search and review of published articles, control-matched, population-based, and co-operative group reports that addressed various aspects of pregnancy after breast cancer (patients' expectations, fertility damage, assessment and preservation, maternal and fetal outcome, breast feeding). Overall, available data support pregnancy and breast feeding after breast cancer as safe and feasible for women at low risk of recurrence. This retrospective and population-based evidence is, however, frequently incomplete; usually not representative of the entire population, it can be biased by patients' related effects or underpowered and is often not controlled for biological factors and risk determinants in the statistical model used. Before making any definitive assumption on this delicate and fundamental aspect of a woman's life after breast cancer, we should demonstrate without any reasonable doubt that the scattered information available today is scientifically sound. The Breast International Group and North American Breast Cancer Group are planning a global prospective study in young women with endocrine responsive, early breast cancer who desire pregnancy, to assess both patients' and pregnancy outcomes. The trial will include an observational phase investigating the feasibility and impact of a temporary treatment interruption to allow conception and an experimental phase investigating the optimal duration of the subsequent endocrine treatment after delivery or the last failed attempt to get pregnant.

show abstract

Section: Methodsmentioning

confidence: 99%

Pregnancy after breast cancer: if you wish, ma’am

Pagani

Partridge

Korde

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Still, how tamoxifen influences ovarian toxicity remains unclear. The suggested mechanisms of interference include the alteration of the hypothalamic-ovarian feedback loop regulating estrogen synthesis and higher plasma estradiol levels, due to the selective estrogen receptor modulation induced by tamoxifen [35,70].…”

Section: Endocrine Treatmentmentioning

confidence: 99%

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer

Torino

Barnabei²,

Vecchis

et al. 2014

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Women presenting FSH levels within the normal range may have suffered significant damage to the ovaries. Studies have shown that FSH levels were significantly higher in women presenting amenorrhea after oncological treatment, however the FSH levels were within the normal range in women with diminished ovarian reserve but regular menstrual cycles [61,62]. Women with diminished ovarian reserve have a limited opportunity window to conceive naturally because they present higher risks of ovarian failure and infertility.…”

mentioning

confidence: 99%

Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact

2016

View full text Add to dashboard Cite

Cancer is a major public health problem around the world. Currently, about 5% of women diagnosed with cancer are of reproductive age. These young survivors may face compromised fertility. The effects of chemotherapeutic agents on ovarian reserve and its clinical consequences are generally inferred from a variety of surrogate markers of ovarian reserve, all aiming to provide prognostic information on fertility or the likelihood of success of infertility treatment. Until recently, the mechanisms that are responsible for chemotherapy-induced ovarian damage were not fully elucidated. The understanding of these mechanisms may lead to targeted treatments to preserve fertility. In this manuscript, we will review the current knowledge on the mechanism of ovarian damage and clinical impact of chemotherapy agents on fertility. Cancer is a major public health problem around the world and is the second leading cause of death in the USA [1]. In 2016, approximately 844,000 new cases of cancer will be diagnosed in women in the USA [1]. In recent years, the remarkable screening, diagnostic and therapeutic advances in oncology practice improved the prognosis for many cancer patients, adding years to their anticipated survival. In fact, all these measures have resulted in a 23% drop in the cancer death rates from 1991 to 2012 [1].Currently, about 5% of cancers affects women younger than 50 years [1]. As young patients with these once-fatal malignancies become long-term survivors, many must face the potentially devastating complications of the treatment. Young survivors will likely face compromised fertility that is now recognized as among the most prevalent long-term side effects of cancer therapy. The prospect of partial or total infertility can significantly add to anxiety and emotional strain during disease management, and may also compromise quality of life [2]. To offset these risks, women can be offered several options for fertility preservation, including conservative cancer management, and cryopreservation of oocyte, embryo or ovarian tissue. Embryo and oocyte cryopreservation are considered established fertility preservation techniques and have been widely applied across the world [3,4]. On the other hand, ovarian tissue cryopreservation is still considered an experimental technique, despite advances in recent years [5].Studies exploring the mechanisms behind the actions of the different chemotherapy agents are providing greater information as to the specific effects of each agent on the different cell types of the ovary. The effects of antineoplastic agents on the ovaries are clinically inferred from a variety This article will review all the mechanism and clinical impact of chemotherapy on ovarian reserve. Ovarian agingThe ovary has a finite endowment of primordial follicles that is established during the second half of intrauterine life, followed by a steady decline until menopause. Each primordial follicle consists of an immature oocyte surrounded by a single layer of granulosa cells. The primordial follicles constit...

show abstract

The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up

Cited by 42 publications

References 22 publications

Pregnancy after breast cancer: if you wish, ma’am

Pregnancy after breast cancer: if you wish, ma’am

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer

Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact

Contact Info

Product

Resources

About